JCR Pharmaceuticals has completed the regulatory review by Japan's PMDA for a Phase I study of JR-441 in patients with mucopolysaccharidosis type IIIA (MPS IIIA).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.